Clinical Trial Update: Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia [Phase 1, Phase 2]

View source ↗

Summary

BRL-101 is in Phase 1/2 trials for transfusion-dependent beta-thalassemia and is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia

Drugs mentioned

• BRL-101

Snippet

Sponsor: Bioray Laboratories | Conditions: Beta-Thalassemia | Phase 1, Phase 2 | Status: ENROLLING_BY_INVITATION